A double whammy for hep C
|
journal
|
June 2003 |
Mericitabine and ritonavir-boosted danoprevir with or without ribavirin in treatment-naive HCV genotype 1 patients: INFORM-SVR study
|
journal
|
June 2014 |
Ribavirin Improves Early Responses to Peginterferon Through Improved Interferon Signaling
|
journal
|
July 2010 |
Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial
|
journal
|
March 2015 |
Using Pharmacokinetic and Viral Kinetic Modeling To Estimate the Antiviral Effectiveness of Telaprevir, Boceprevir, and Pegylated Interferon during Triple Therapy in Treatment-Experienced Hepatitis C Virus-Infected Cirrhotic Patients
|
journal
|
June 2014 |
Ribavirin potentiates interferon action by augmenting interferon-stimulated gene induction in hepatitis C virus cell culture models
|
journal
|
October 2010 |
A Viral Dynamic Model for Treatment Regimens with Direct-acting Antivirals for Chronic Hepatitis C Infection
|
journal
|
January 2012 |
Second-phase hepatitis C virus RNA decline during telaprevir-based therapy increases with drug effectiveness: Implications for treatment duration
|
journal
|
May 2011 |
Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection
|
journal
|
January 1995 |
Modeling Viral Evolutionary Dynamics after Telaprevir-Based Treatment
|
journal
|
August 2014 |
Antiviral Suppression vs Restoration of RIG-I Signaling by Hepatitis C Protease and Polymerase Inhibitors
|
journal
|
November 2008 |
Decay characteristics of HIV-1-infected compartments during combination therapy
|
journal
|
May 1997 |
Is There a Role for Ribavirin in the Era of Hepatitis C Virus Direct-Acting Antivirals?
|
journal
|
May 2012 |
Quantifying the Diversification of Hepatitis C Virus (HCV) during Primary Infection: Estimates of the In Vivo Mutation Rate
|
journal
|
August 2012 |
Post-Treatment HIV-1 Controllers with a Long-Term Virological Remission after the Interruption of Early Initiated Antiretroviral Therapy ANRS VISCONTI Study
|
journal
|
March 2013 |
HCV Kinetic Models and Their Implications in Drug Development: HCV Kinetic Models and Their Implications
|
journal
|
April 2015 |
Virological response after 6 week triple-drug regimens for hepatitis C: a proof-of-concept phase 2A cohort study
|
journal
|
March 2015 |
Modeling viral kinetics and treatment outcome during alisporivir interferon-free treatment in hepatitis C virus genotype 2 and 3 patients: HEPATOLOGY, Vol. XX, NO. X, 2014 GUEDJ ET AL.
|
journal
|
April 2014 |
Pharmacodynamics of PEG-IFN-α-2a in HIV/HCV co-infected patients: Implications for treatment outcomes
|
journal
|
September 2010 |
A phase 2a trial of 12-week interferon-free therapy with two direct-acting antivirals (ABT-450/r, ABT-072) and ribavirin in IL28B C/C patients with chronic hepatitis C genotype 1
|
journal
|
July 2013 |
A Pharmacokinetic–Viral Kinetic Model Describes the Effect of Alisporivir as Monotherapy or in Combination With Peg-IFN on Hepatitis C Virologic Response
|
journal
|
August 2014 |
Analysis of Hepatitis C Virus Infection Models with Hepatocyte Homeostasis
|
journal
|
January 2009 |
Viral kinetic modeling: state of the art
|
journal
|
June 2014 |
A Hepatitis C Virus Infection Model with Time-Varying Drug Effectiveness: Solution and Analysis
|
journal
|
August 2014 |
Early and Accurate Prediction of Peg-IFNs/Ribavirin Therapy Outcome in the Individual Patient With Chronic Hepatitis C by Modeling the Dynamics of the Infected Cells
|
journal
|
March 2008 |
Utility of Hepatitis C Viral Load Monitoring on Direct-Acting Antiviral Therapy
|
journal
|
March 2015 |
Analysis of Hepatitis C Virus Decline during Treatment with the Protease Inhibitor Danoprevir Using a Multiscale Model
|
journal
|
March 2013 |
Kinetic Analyses Reveal Potent and Early Blockade of Hepatitis C Virus Assembly by NS5A Inhibitors
|
journal
|
August 2014 |
Post-treatment control of HIV infection
|
journal
|
April 2015 |
Understanding hepatitis C viral dynamics with direct-acting antiviral agents due to the interplay between intracellular replication and cellular infection dynamics
|
journal
|
December 2010 |
Mathematical analysis of multiscale models for hepatitis C virus dynamics under therapy with direct-acting antiviral agents
|
journal
|
September 2013 |
Review article: predicting response in hepatitis C virus therapy
|
journal
|
April 2006 |
Hepatocyte Proliferation and Hepatitis C Virus Kinetics During Treatment
|
journal
|
January 2011 |
Correlation between the infectivity of hepatitis C virus in vivo and its infectivity in vitro.
|
journal
|
July 1993 |
Type I interferon rapidly restricts infectious hepatitis C virus particle genesis
|
journal
|
September 2014 |
Interferon γ–Induced Protein10 Kinetics in Treatment-Naive Versus Treatment-Experienced Patients Receiving Interferon-Free Therapy for Hepatitis C Virus Infection: Implications for the Innate Immune Response
|
journal
|
June 2014 |
Very late relapse after discontinuation of antiviral therapy for chronic hepatitis C
|
journal
|
January 2013 |
Importance of very early HCV RNA kinetics for prediction of treatment outcome of highly effective all oral direct acting antiviral combination therapy
|
journal
|
March 2015 |
Sofosbuvir and Ribavirin for Hepatitis C Genotype 1 in Patients With Unfavorable Treatment Characteristics: A Randomized Clinical Trial
|
journal
|
August 2013 |
A Comprehensive Hepatitis C Viral Kinetic Model Explaining Cure
|
journal
|
May 2010 |
Differences in Viral Dynamics between Genotypes 1 and 2 of Hepatitis C Virus
|
journal
|
July 2000 |
Modeling hepatitis C virus dynamics: Liver regeneration and critical drug efficacy
|
journal
|
July 2007 |
Rapid Emergence of Protease Inhibitor Resistance in Hepatitis C Virus
|
journal
|
May 2010 |
Triphasic decline of hepatitis C virus RNA during antiviral therapy
|
journal
|
January 2007 |
Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon
|
journal
|
June 2003 |
HIV-1 Dynamics in Vivo: Virion Clearance Rate, Infected Cell Life-Span, and Viral Generation Time
|
journal
|
March 1996 |
Antiviral action of ribavirin in chronic hepatitis C
|
journal
|
March 2004 |
Pharmacokinetic/Pharmacodynamic Predictors of Clinical Potency for Hepatitis C Virus Nonnucleoside Polymerase and Protease Inhibitors
|
journal
|
April 2012 |
Effect of ribavirin on viral kinetics and liver gene expression in chronic hepatitis C
|
journal
|
February 2013 |
Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis
|
journal
|
May 2014 |
Pharmacodynamics of PEG-IFN α differentiate HIV/HCV coinfected sustained virological responders from nonresponders
|
journal
|
May 2006 |
Modeling Subgenomic Hepatitis C Virus RNA Kinetics during Treatment with Alpha Interferon
|
journal
|
April 2009 |
A Multi-Variant, Viral Dynamic Model of Genotype 1 HCV to Assess the in vivo Evolution of Protease-Inhibitor Resistant Variants
|
journal
|
April 2010 |
Sporadic Reappearance of Minute Amounts of Hepatitis C Virus RNA After Successful Therapy Stimulates Cellular Immune Responses
|
journal
|
February 2011 |
Novel Hepatitis C Virus Reporter Replicon Cell Lines Enable Efficient Antiviral Screening against Genotype 1a
|
journal
|
June 2010 |
Highly Permissive Cell Lines for Subgenomic and Genomic Hepatitis C Virus RNA Replication
|
journal
|
December 2002 |
Rapid HCV-RNA Decline With Once Daily TMC435: A Phase I Study in Healthy Volunteers and Hepatitis C Patients
|
journal
|
March 2010 |
Replication Vesicles are Load- and Choke-Points in the Hepatitis C Virus Lifecycle
|
journal
|
August 2013 |
A pharmacokinetic/viral kinetic model to evaluate the treatment effectiveness of danoprevir against chronic HCV
|
journal
|
January 2014 |
Modeling HCV kinetics under therapy using PK and PD information
|
journal
|
March 2009 |
Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect
|
journal
|
April 2010 |
Characterization of hepatitis C virus intergenotypic recombinant strains and associated virological response to sofosbuvir/ribavirin
|
journal
|
December 2014 |
Very late HCV relapse following triple therapy for hepatitis C
|
journal
|
January 2014 |
Hepatitis C Viral Dynamics in Vivo and the Antiviral Efficacy of Interferon- Therapy
|
journal
|
October 1998 |
Modelling how ribavirin improves interferon response rates in hepatitis C virus infection
|
journal
|
December 2004 |
Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients
|
journal
|
September 2007 |
Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life
|
journal
|
February 2013 |
Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial
|
journal
|
October 2010 |
Interaction Index and Different Methods for Determining Drug Interaction in Combination Therapy
|
journal
|
May 2007 |
Kinetics of hepatitis C virus RNA decay, quasispecies evolution and risk of virological failure during telaprevir-based triple therapy in clinical practice
|
journal
|
March 2015 |
Modeling Within-Host Dynamics of Influenza Virus Infection Including Immune Responses
|
journal
|
June 2012 |
Efficacy of Nucleotide Polymerase Inhibitor Sofosbuvir Plus the NS5A Inhibitor Ledipasvir or the NS5B Non-Nucleoside Inhibitor GS-9669 Against HCV Genotype 1 Infection
|
journal
|
March 2014 |
Severity of liver disease affects HCV kinetics in patients treated with intravenous silibinin monotherapy
|
journal
|
January 2014 |
The metabolism, pharmacokinetics and mechanisms of antiviral activity of ribavirin against hepatitis C virus
|
journal
|
February 2006 |
Hepatitis C viral kinetics with the nucleoside polymerase inhibitor mericitabine (RG7128)
|
journal
|
February 2012 |
Viral dynamics in human immunodeficiency virus type 1 infection
|
journal
|
January 1995 |
1172 Antiviral Activity and Resistance Profile of the Novel hcv ns5a Inhibitor Gs-5885
|
journal
|
April 2012 |
Modeling Quasispecies and Drug Resistance in Hepatitis C Patients Treated with a Protease Inhibitor
|
journal
|
May 2012 |
Viral Kinetics in Patients with Chronic Hepatitis C Treated with the Serine Protease Inhibitor Biln 2061
|
journal
|
April 2005 |
Modelling Hepatitis C virus Kinetics: The Relationship between the Infected Cell Loss rate and the Final Slope of Viral Decay
|
journal
|
April 2008 |
Applying Regular Perturbation Analysis to HCV Viral Load Equations
|
book
|
April 2010 |
A Hepatitis C Viral Kinetic Model that Allows for Time-Varying Drug Effectiveness
|
journal
|
October 2008 |
Rapid decrease of wild-type hepatitis C virus on telaprevir treatment
|
journal
|
May 2008 |